Curaleaf: Aurora Cannabis Acquisition Bid Receives Competition Clearances In Canada And Germany

Curaleaf Holdings has received all required competition law clearances for its proposed acquisition of Aurora Cannabis, strengthening its position in a contested takeover process involving a competing acquisition agreement between Aurora and Organigram Global.

The regulatory approvals were obtained in Germany and Canada, the only jurisdictions in which Curaleaf’s proposed transaction required competition law clearance.

Germany’s Federal Ministry for Economic Affairs and Energy approved the proposed acquisition of Aurora’s German operating entities on October 20, 2026.

The approval covers Aurora Europe, Aurora Deutschland, and Aurora Produktions.

On November 2, Canada’s Competition Bureau issued a no-action letter regarding Curaleaf’s proposed acquisition of Aurora shares.

The letter indicated that the regulator had completed its review and did not currently intend to challenge the transaction under the applicable provision of Canada’s Competition Act.

Germany’s Federal Cartel Office subsequently confirmed on November 3 that the proposed acquisition did not meet the conditions for prohibition under German competition law.

The regulatory clearances remove an important potential obstacle to Curaleaf’s proposed transaction.

However, receiving competition approvals does not mean that its acquisition of Aurora has been completed.

Curaleaf’s enhanced takeover offer, announced October 6, remains outstanding.

The offer is scheduled to expire on December 4, 2026, unless it is withdrawn or amended.

Completion will depend on the satisfaction or waiver of the remaining conditions.

The regulatory announcement comes as Aurora evaluates competing acquisition proposals.

Organigram previously announced an agreement to acquire Aurora in a transaction valuing the company at approximately C$561 million on a fully diluted equity basis.

The Organigram arrangement offers Aurora shareholders different combinations of cash and shares.

That transaction remains subject to shareholder, court, regulatory, and other approvals.

Curaleaf believes its completed competition reviews provide greater certainty regarding the potential closing of its own proposal.

The company is emphasizing regulatory progress as Aurora shareholders consider the alternatives.

The competing transactions reflect interest in combining businesses with established medical and recreational cannabis operations across international markets.

Aurora has developed a significant presence in medical cannabis, including operations serving European markets.

Curaleaf operates consumer and medical cannabis businesses in North America and internationally.

Its international activities include production, distribution, and commercial relationships across Europe, Canada, and Australasia.

The company’s portfolio includes brands such as Curaleaf, Select, Grassroots, Dark Heart, and Anthem.

A potential combination with Aurora could provide Curaleaf with additional assets and capabilities across regulated cannabis markets.

However, any potential benefits would depend on successful completion and integration.

The latest announcement does not change the fact that Aurora is involved in an active takeover contest.

Curaleaf’s offer remains subject to its existing terms and completion requirements.

The company believes its completed regulatory process offers shareholders an important consideration as they evaluate the proposals.

The transaction’s outcome will depend on shareholder decisions and the remaining conditions associated with the competing offers.

KEY QUOTE:

“With all required competition law clearances secured, the path is clear for Aurora shareholders to realize the value our Offer provides. We appreciate the constructive engagement of the regulators who reviewed the transaction.”

Boris Jordan, Chairman And CEO Of Curaleaf Holdings